The marked variability in age at onset of colorectal cancer (CRC) in patients with hereditary nonpolyposis colorectal cancer (HNPCC) makes management decisions difficult. Environmental factors governing the phenotypic variability of cancer-associated syndromes such as HNPCC have not been elucidated.
We determined whether tobacco use would alter CRC risk in carriers of HNPCC-associated mutations, using a retrospective cohort study of germline mutation (hMLH1 or hMSH2) carriers from the Hereditary Cancer Institute at Creighton University, one of the oldest and largest registries of HNPCC patients. The main outcome measure was age at CRC onset, estimated by means of Cox proportional hazards modeling.
Tobacco use, hMLH1 mutation carriage (as opposed to hMSH2), and male sex were significantly associated with increased risk of CRC (hazard ratios, 1.43, 2.07, and 1.58, respectively). Alcohol use did not alter CRC risk.
Smoking cessation should be an integral part of HNPCC management. This study underscores the gene × environment interactions in cancer development.
Approximately one quarter of the 138 000 new colorectal cancer (CRC) cases diagnosed annually in the United States are familial. Hereditary nonpolyposis colorectal cancer (HNPCC) syndrome, or Lynch syndrome, is one of the most common CRC predisposing conditions, engendering a greater than 70% lifetime risk of CRC, along with several extracolonic malignancies (endometrial, ovarian, gastric, hepatobiliary, upper uroepithelial tract, and brain malignancies).1 This autosomal dominant condition is caused by a germline mutation in DNA mismatch repair genes (most often hMLH1 or hMSH2).2
There are marked variations in age at presentation of CRC.3 Understanding the determinants of this phenotypic heterogeneity is critical in tailoring cancer prevention strategies for individual high-risk patients. Tobacco use is known to be a cofactor in a large number of tumors. There is a wealth of epidemiologic data linking colorectal adenoma development to smoking,4- 8 but the evidence on CRC is inconsistent and, hence, less compelling. Recently, this relationship has been clarified by several demonstrations that cigarette smoking selectively increases the subset of CRC that manifests high microsatellite instability (MSI-high).9- 10 The MSI-high tumors make up approximately 15% to 20% of all CRCs and are the molecular hallmark of HNPCC. Alcohol consumption has also been shown to increase the risk of CRC.11- 15 It has recently been reported that ethanol potentiates adenomas in a genetic model of colon carcinogenesis.16
There are no previous reports on the role of environmental factors modulating the clinical manifestations of HNPCC, to our knowledge. We, therefore, analyzed HNPCC germline mutation carriers in our database to ascertain whether tobacco or alcohol use was associated with the risk of CRC.
The Hereditary Cancer Institute at Creighton University is one of the oldest and largest HNPCC registries. All registered families with at least 1 known mutation carrier were examined, and tested or inferred carriers were identified. Inferences about carrier status were based on the assumption that all tested carriers in the family inherited the mutation from a common ancestor. Data on the history of tobacco and alcohol use were sought on all carriers. These data were obtained by self-report or family report or from medical records. An individual was classified as a tobacco user if he or she was known to ever regularly use any tobacco product; the individual was classified as an alcohol user if he or she reported past or current regular consumption of 1 or more drinks per week.
Time from birth to first CRC diagnosis was analyzed using Cox proportional hazards modeling. Tobacco use or, in a separate analysis, alcohol use was the independent variable of interest, with the following potential confounders included in the models: sex, year of birth cohort (before vs during or after 1948), and gene affected (hMLH1 vs hMSH2). In a secondary analysis, we analyzed the quantity of cigarette consumption in the subset of patients in whom pack-year data were available. Analyses were performed using SAS/Stat for Windows (SAS Institute, Cary, NC). This study was approved by Creighton University’s Institutional Review Board.
We identified 596 mutation carriers from 62 HNPCC families. Of these carriers, 360 had information on tobacco use (so that they could be classified as users or nonusers) and were included in our study. Characteristics of this group are given in Table 1.
The results of Cox proportional hazards modeling are given in Table 2. Tobacco users had a higher incidence of CRC than nonusers, reflected in a hazard ratio of 1.43 (P<.04). In addition, hMLH1 carriers (vs hMSH2 carriers) and men (vs women) were at a statistically significant increased risk of CRC. Year of birth cohort was not associated with an altered hazard ratio for CRC. Substituting the year of birth for the year of birth cohort in the model did not improve the model fit. Including terms for sex, gene, or time (from birth) interactions with tobacco use also did not improve the model fit, indicating that the Cox proportional hazards model was appropriate for these data.
In patients who smoked cigarettes and provided data on amount smoked (113 of 182 smokers), the mean consumption was 24 pack-years. Cox proportional hazards modeling failed to demonstrate a significant correlation between CRC risk and increasing pack-years of use.
Alcohol use information was available in 271 carriers, of whom 83 (30.6%) were classified as nonusers. Cox proportional hazards modeling failed to show a significant association between alcohol use and CRC risk (P>.40). A second analysis of these cases that included tobacco use and a tobacco use × alcohol use interaction term in the model also showed no significant association between alcohol use or the interaction term and CRC risk.
The pathogenesis of the phenotypic variability in HNPCC is poorly understood. To date, the most compelling arguments for environmental modulation have been geographic differences in cancer rates. For instance, in Korea, where sporadic gastric cancer is endemic secondary to dietary practices, HNPCC patients have a much higher incidence of gastric cancer than comparable Dutch families.17 Tobacco use is a biologically plausible modulator of the CRC risk in HNPCC because smoking predominantly potentiates MSI-high colon cancer.9 In the general population, 12% of all CRC fatalities are attributable to smoking.18 The 43% increased hazard ratio seen in this study is the first evidence, to our knowledge, of an environmental modulation of cancer risk in HNPCC. This appeared to be unrelated to the amount of total exposure. The lack of a dose-response effect may reflect a threshold effect, in which environmental effects are seen at lower levels of exposure in the highly susceptible group.19 However, speculation needs to be tempered by the limited number of subjects available and by the limitations inherent in any observational study. The lack of a dose-response effect may indicate that the association between tobacco use and colon cancer is noncausal and a result of confounding, which (although unlikely) is impossible to rule out in an observational study. The lack of association between alcohol use and CRC risk is consistent with several reports that suggest that alcohol predominantly augments distal CRC,12 which is unlikely to be MSI-high.20 Indeed, the one report21 of a minimal increase in MSI-high tumors with alcohol use was noted for liquor consumption, but not wine or beer. Taken together, the evidence suggests that alcohol-induced CRC evolves through a molecular pathway distinct from HNPCC-related CRC. Although we did not explore the mechanisms through which tobacco use might increase CRC risk, it is most likely a result of the numerous carcinogens in cigarette smoke.22 Given the deficiency of DNA mismatch repair in HNPCC, these patients may be particularly susceptible to mutagenic effects of tobacco-induced DNA adducts.23
To our knowledge, this is the first report that hMLH1 mutation carriers had a higher risk of developing CRC than hMSH2 carriers. Previous reports from the Netherlands24 and Australia25 yielded discordant trends for CRC risk in hMLH1 and hMSH2 mutation carriers, but in neither case was the trend statistically significant. Both studies were smaller than the present study. We confirm the previously reported increase in CRC hazard ratio in men vs women.24,26- 27 Sex differences may result from genetic and environmental factors (estrogens are clearly protective against CRC).28
There are several limitations inherent in our retrospective study. The incomplete smoking data raise concerns about bias, including selection bias (carriers with tobacco use data may be unrepresentative of carriers as a whole) and response bias (patients with CRC might be more likely to remember or report tobacco use). However, post hoc comparisons of carriers with and without smoking data argued against important selection bias, showing no differences in sex ratio, year of birth, or proportion with CRC. Our inclusion of inferred carriers should also mitigate selection bias. Biased reporting of tobacco or alcohol use may occur in subjects with cancer, but because CRC is not widely believed to be a smoking-related tumor, we do not think that this is plausible. Future studies of the relationship between tobacco use and CRC in HNPCC should include more detailed tobacco use history information (unavailable for most cases in this study), to obtain more accurate estimates of the strength of the association and to study its temporal pattern.
In summary, we report for the first time (to our knowledge) that an exogenous factor, tobacco use, appears to modulate the penetrance of a genetic CRC susceptibility disorder caused by germline mismatch repair mutations. We also believe that this is the first demonstration of a statistically significant difference in CRC risk between the 2 most common loci for germline mutations in HNPCC, hMLH1 and hMSH2. These data underscore the complex genetic and environmental factors in the pathogenesis of CRC. Our results suggest that cigarette smoking cessation should be an integral part of the management of patients with HNPCC. Furthermore, this study may serve as a paradigm for risk stratification of patients with an inherited predisposition for cancers to implement optimal prevention strategies.
Correspondence: Patrice Watson, PhD, Department of Preventive Medicine and Public Health, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178 (firstname.lastname@example.org).
Accepted for Publication: April 15, 2004.
Financial Disclosure: None.
Funding/Support: This research was funded by a clinical research award from the American College of Gastroenterology, Alexandria, Va (Drs Lynch and Roy). The work of Drs Watson, Ashwathnarayan, and Lynch was also supported by revenue from Nebraska cigarette taxes awarded to Creighton University by the Nebraska Department of Health and Human Services, Lincoln.
Disclaimer: The results reported in this article are solely the responsibility of the authors and do not necessarily represent the official views of the state of Nebraska or the Nebraska Department of Health and Human Services.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 32
Customize your page view by dragging & repositioning the boxes below.
Users' Guides to the Medical Literature
Users' Guides to the Medical Literature
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.